Following potential billion-dollar J&J deal, RNA processing biotech Remix returns with fresh financing
A few months ago, Remix Therapeutics penned a deal with Johnson & Johnson that could end up being worth more than $1 billion dollars down the line.
Now, Remix is back with $70 million in new financing as it continues to develop its RNA processing technology, the company announced this morning. The Cambridge, MA-based biotech houses a discovery platform aimed at drugging RNA processing, the unsung (difficult) middle child in a pharma world that has largely paid more heed to protein targets and DNA therapies until recently.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.